Zealand Pharma A/S (ZLDPF)
OTC PINK OTC PINK Primary 
Zealand Pharma A/S (ZLDPF) Reports Q3 Loss, Lags Revenue Estimates
Zealand Pharma A/S (ZLDPF) came out with a quarterly loss of $0.56 per share versus the Zacks Consensus Estimate of a loss of $0.62. This compares to earnings of $0.18 per share a year ago.
Zealand Pharma to start phase 2b trial for obesity drug candidate in Q4
Danish biotechnology company Zealand Pharma said on Thursday it expected to initiate a phase 2b trial with its obesity treatment candidate petrelintide in the fourth quarter of 2024.
Zealand Pharma seeks partner for its 'next generation' weight loss drug
CNBC's Karen Gilchrist weighs in on Zealand Pharma's "next generation" obesity drug candidate and its search for a global partner.
Zealand Pharma targeting 'next generation' of obesity drugs, CEO says
Zealand Pharma's CEO Adam Steensberg weighs in on early-stage trials of its obesity drug contender and talks down takeover speculation.
Wegovy and Zepbound rival targeting 'next generation' of obesity drugs, Zealand Pharma CEO says
Danish biotech Zealand Pharma is targeting the "next generation" of weight loss drugs as competitors pile into a market dominated by heavyweights Novo Nordisk and Eli Lilly. CEO Adam Steensberg heralded early-stage trial results of its GLP-1 treatment in an interview with CNBC, but said it was the company's separate obesity drug candidate that sets it apart.
Recent Price Trend in Zealand Pharma AS (ZLDPF) is Your Friend, Here's Why
Zealand Pharma AS (ZLDPF) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.
Zealand Pharma AS (ZLDPF) Is a Great Choice for 'Trend' Investors, Here's Why
Zealand Pharma AS (ZLDPF) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.
Here's Why Momentum in Zealand Pharma AS (ZLDPF) Should Keep going
If you are looking for stocks that are well positioned to maintain their recent uptrend, Zealand Pharma AS (ZLDPF) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.
Zealand Pharma seeks big pharma partners for obesity drug candidate
Denmark's Zealand Pharma is set to start talks in the second half of this year with other pharmaceutical companies for potential partnerships to develop and commercialize its weight-loss drug petrelintide, its CEO told Reuters on Thursday.
Strength Seen in Zealand Pharma AS (ZLDPF): Can Its 11.6% Jump Turn into More Strength?
Zealand Pharma AS (ZLDPF) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Weight loss drug contender Zealand Pharma jumps 23% on trial results
Zealand Pharma shares popped on Friday on positive weight loss results from long-acting amylin analog petrelintide. The company said petrelintide may produce similar weight loss results and a "better patient experience" than GLP-1RA-based treatments, which include Novo Nordisk's Ozempic and Wegovy.
Zealand Pharma's drug reduces weight by 8.6% in early-stage study
Zealand Pharma said on Thursday an early-stage study showed a high dose of its drug helped reduce weight by an average 8.6% after 16 weekly doses.
